LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

96.23 -1.54

Resumen

Variación precio

24h

Actual

Mínimo

95.85

Máximo

96.87

Métricas clave

By Trading Economics

Ingresos

2.9M

-47M

Ventas

16M

49M

Margen de beneficios

-96.144

Empleados

283

EBITDA

6.9M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+16.48% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

672M

6.6B

Apertura anterior

97.77

Cierre anterior

96.23

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

148 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2025, 22:41 UTC

Principales Movimientos del Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept 2025, 16:04 UTC

Principales Movimientos del Mercado

Upexi Shares Climb on Solana Gains

14 sept 2025, 23:48 UTC

Charlas de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sept 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sept 2025, 23:38 UTC

Charlas de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 sept 2025, 23:04 UTC

Charlas de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sept 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 20:09 UTC

Ganancias

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:16 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:03 UTC

Charlas de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept 2025, 18:59 UTC

Charlas de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept 2025, 18:38 UTC

Charlas de Mercado
Ganancias

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept 2025, 18:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept 2025, 18:22 UTC

Charlas de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept 2025, 16:56 UTC

Charlas de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept 2025, 16:22 UTC

Ganancias

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

12 sept 2025, 16:11 UTC

Ganancias

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept 2025, 15:37 UTC

Charlas de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept 2025, 15:22 UTC

Charlas de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept 2025, 15:07 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

16.48% repunte

Estimación a 12 Meses

Media 112.08 USD  16.48%

Máximo 135 USD

Mínimo 95 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

148 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat